20n Bio Raises $3.3M in Seed Funding
Summary
20n Bio, a Malvern, Pa.-based artificial intelligence (AI)-powered drug discovery company focusing on designing new proteins for therapeutics, raised $3.3m in seed funding. The company will use the funds to expand its scientific team, establish its discovery platform, and start multiple early studies in oncology and other genetic diseases. Launched in 2021, the company aims to address unmet medical needs by leveraging artificial intelligence to generate protein drugs in silico with desired biophysical, functional, and pharmacological properties. The company recently added two computational structural biologists Dr. Yaoqi Zhou at Shenzhen Bay Laboratory, and Dr. Longxing Cao at Westlake University who is a finalist of the MIT Technology Review Innovators Under 35 Asia Pacific 2021 to its Scientific Advisory Board. Dr. Zhu was an assistant professor at Duke University Medical Center and held multiple executive roles at leading US and Chinese biotech companies.
Funding
Review available funding amount, funding date, investors, and linked company information related to 20n Bio Raises $3.3M in Seed Funding in the interactive ISVWorld profile.